AzTrials
AzTrials

Atrial FibrillationSHOCK-VECTORNCT05511389

Anteroposterior Versus Anterolateral Electrode Position for Electrical Cardioversion of Atrial Fibrillation

A study testing Anterolateral electrode position, Anteroposterior electrode position and Manual pressure in people with Atrial Fibrillation and Atrial Flutter, run by McMaster University at 4 sites in Canada.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Atrial fibrillation is the most common heart rhythm disorder (arrhythmia) worldwide. Nearly 40 million people are affected by atrial fibrillation worldwide, and this number is expected to increase by over 50% by 2050. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Atrial Fibrillation, Atrial Flutter
What is being tested?
Anterolateral electrode position, Anteroposterior electrode position and Manual pressure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,750 participants
Where
4 sitesCanada
Study dates
22 Feb 2023to Aug 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Consenting adult patients scheduled for non-emergent electrical cardioversion of Atrial Fibrillation or Flutter

Who cannot join

  • Insufficiently anticoagulation for cardioversion as per Canadian Cardiovascular Society guidelines or have not undergone trans-esophageal echocardiography to rule out left atrial thrombus
  • Anatomic contraindication to anterolateral or anteroposterior placement (e.g. skin conditions or wounds)

Trial locations and contacts

4 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Canada4 sites, 3 recruiting
  • Hamilton Health Sciences

    Hamilton, Ontario, L8L2X2

    William McIntyre, MD, William.mcintyre@Phri.ca

    Recruiting
  • Institut de cardiologie de Montréal

    Montreal, Quebec

    Active, not recruiting
  • Institut Universitaire De Cardiologie Et De Pneumologie de Québec

    Québec, Quebec

    Christian Steinberg

    Recruiting
  • Women's College Hospital

    Toronto, Ontario

    Husam Abdel-Qadir

    Recruiting

Other trials in Canada

About this study

Official title: A Randomized Controlled Trial of Anterior-posterior Versus Anterior-lateral Shock Vectors for Electrical Cardioversion of Atrial Fibrillation

Atrial fibrillation is the most common heart rhythm disorder (arrhythmia) worldwide. Nearly 40 million people are affected by atrial fibrillation worldwide, and this number is expected to increase by over 50% by 2050. Atrial fibrillation can cause strokes, heart attacks, heart failure, poor quality of life and even death. Almost half a million deaths worldwide are expected to be related to atrial fibrillation by 2050, and many billions of dollars are spent on atrial fibrillation related healthcare in North America every year.

We believe health outcomes for patients with atrial fibrillation, and healthcare costs associated with treating atrial fibrillation could be improved by optimizing existing treatments for atrial fibrillation and maximizing the likelihood of restoring normal heart rhythm. This allows them to benefit from lower stroke risk, better heart function, fewer symptoms and increased quality of life. Restoring normal sinus rhythm earlier prevents atrial fibrillation from causing permanent structural damage to the heart that in turn, makes atrial fibrillation intractable. Furthermore, patients in whom initial attempts to control atrial fibrillation are unsuccessful frequently require more medications or invasive catheter ablation procedures which are costly and carry substantial risk.

Read more

Electrical cardioversion is the main way physicians restore normal heart rhythm. In this procedure, the heart is "shocked" back into normal rhythm using two electrodes on the chest. Done correctly, this procedure is safe and effective. Many things are known about electrical cardioversion, for example, the best type and amount of electricity to use. What we don't know is the best position of the electrodes on the chest and whether applying direct, physical pressure to the electrodes makes cardioversion more successful. Our prior research suggests that improving positioning and applying pressure may improve cardioversion, but this finding needs to be verified with a rigorous, dedicated trial.

This study will demonstrate whether front-to-back, or front-to-side placement of the electrodes is more effective for electrical cardioversion of atrial fibrillation. We will also demonstrate whether manually applying pressure to the electrodes makes cardioversion more effective. Should our trial demonstrate a benefit for these techniques, we expect them to be universally applied around the world. Because hundreds of thousands of cardioversions are done each year, even small increases in cardioversion success means thousands fewer patients progress to needing more medications or invasive procedures to manage their atrial fibrillation.

We will study consenting adults presenting for non-urgent cardioversion of their atrial fibrillation. After explaining the study to participants and gaining their consent, we will randomly assign them to front-to-side or front-to-back electrode placement. Patients who remain in atrial fibrillation after the first shock will randomly receive either manual pressure or not. We will compare the success of cardioversion for front-side versus front-back electrode placement, and for manual pressure versus none. We will evaluate success by using electrocardiograms to assess for restoration of the heart rhythm back to normal.

We hypothesize that anterolateral electrode positioning is superior to anteroposterior electrode positioning. We also hypothesize that manual pressure is effective relative to none, when applied in patients who have had one unsuccessful shock already.

Being tested
Anterolateral electrode position, Anteroposterior electrode position, Manual pressure
Medical subject headings
Atrial Fibrillation, Atrial Flutter

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Anterolateral electrode positionOther

    As described previously

  • Anteroposterior electrode positionOther

    As described previously

  • Manual pressureOther

    Manual pressure applied to the anterior electrode

Study groups in NCT05511389
Study groupRoleWhat they receive
Anterolateral shock vectorActive comparatorPatients with electrodes placed on the chest to obtain an anterolateral (front-to-side placement; also known as anteroapical) shock vector. If first shock is unsuccessful, participants who proceed to a second shock will be randomized to manual pressure versus none but electrode placement will remain the same.
Receives: Other: Anterolateral electrode position; Other: Manual pressure
Anteroposterior shock vectorActive comparatorPatients with electrodes placed on the chest to obtain an anteroposterior (front-to-back placement) shock vector. If first shock is unsuccessful, participants who proceed to a second shock will be randomized to manual pressure versus none but electrode placement will remain the same.
Receives: Other: Anteroposterior electrode position; Other: Manual pressure

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. First-shock cardioversion success

    Reversion to sinus rhythm (5 consecutive P waves within 5 seconds of shock)

    Measured: At time of intervention

Secondary outcomes (2)
  1. Cumulative cardioversion success for anterolateral versus anteroposterior placement afte

    Reversion to sinus rhythm (5 consecutive P waves within 5 seconds of shock)

    Measured: At time of intervention

  2. Second shock success for manual pressure versus none

    Reversion to sinus rhythm (5 consecutive P waves within 5 seconds of shock)

    Measured: At time of intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Aug 2022
  2. Study start22 Feb 2023
  3. Primary completionJul 2028 (estimated)
  4. Study completionAug 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
With a partial factorial randomization to manual pressure versus not (second intervention) if the first randomized attempt is unsuccessful at restoring normal heart rhythm
Masking
None (open label)
Enrolment
1,750 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05511389
Sponsor's protocol ID
5173
Acronym
SHOCK-VECTOR
Status last verified
Jul 2026
First submitted
19 Aug 2022
Last updated
16 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Anterolateral electrode position, Anteroposterior electrode position and Manual pressure in people with Atrial Fibrillation and Atrial Flutter, run by McMaster University at 4 sites in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 16 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact William McIntyre, MD (9055212100 ext. 40631, william.mcintyre@phri.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

First-shock cardioversion success (time frame: At time of intervention). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in